Phosphoric Acid

Phosphoric Acid

SCHEMBL340431

CCCCCCCCCCCCCC(=O)NCCCN(C)C.O=P(O)(O)O

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 2/20 0.88
FAAH O00519 5/20 0.57
LPAR1 Q92633 4/20 0.56
NAAA Q02083 1/20 0.56
CASP2 P42575 1/20 0.54
LPAR2 Q9HBW0 3/20 0.50
ENPP2 Q13822 1/20 0.50
EPHX2 P34913 2/20 0.49
SELP P16109 1/20 0.49
THRA P10827 1/20 0.48
THRB P10828 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL9843964 1.00 DNM1 (0.88) DNM1FAAHLPAR1NAAACASP2
SCHEMBL9565176 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2
SCHEMBL8660980 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2
SCHEMBL19281112 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2
SCHEMBL74418 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2
SCHEMBL8780431 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2
SCHEMBL3318222 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2
SCHEMBL15994307 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2
SCHEMBL5383341 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2
SCHEMBL7924413 0.94 DNM1 (1.00) DNM1FAAHNAAACASP2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190099342-A1 COOLING PRODUCT SYMRISE AG (DE) 2019-04-04 US claimed
US-8158567-B1 Body cleansing composition DEANE JEFFREY ALAN (US) 2012-04-17 US claimed
US-7977290-B1 Body cleansing composition DEANE JEFFREY ALAN 2011-07-12 US claimed
WO-2008081348-A2 METHOD AND COMPOSITION FOR PERMANENTLY SHAPING HAIR THE PROCTER & GAMBLE COMPANY (US) 2008-07-10 WO claimed
US-20080025937-A1 Method and composition for permanently shaping hair PROCTER & GAMBLE COMPANY, THE 2008-01-31 US claimed
EP-1880709-A1 Method and composition for permanently shaping hair Wella Aktiengesellschaft (DE) 2008-01-23 EP claimed
EP-0437006-B1 Composition that protects dyed hair from fading COLGATE PALMOLIVE CO (US) 1994-12-07 EP claimed
EP-0437006-A1 Composition that protects dyed hair from fading Colgate-Palmolive Company (US) 1991-07-17 EP claimed
US-12629327-B2 Keratin-based hair straightening formulations, methods and systems BEAUTY BIOLABS LLC (US) 2026-05-19 US disclosed
WO-2026087745-A1 AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE BRAIN Biotech AG (DE) 2026-04-30 WO disclosed
EP-4732825-A1 AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE BRAIN Biotech AG (DE) 2026-04-29 EP disclosed
US-20260096978-A1 A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS SYMRISE AG (DE) 2026-04-09 US disclosed
EP-4025675-B1 A PERFUME OIL MIXTURE SYMRISE AG (DE) 2026-03-18 EP disclosed
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2026-02-19 US disclosed
EP-0757560-A1 USE OF AMIDOAMINES IN OPHTHALMIC COMPOSITIONS ALCON LABORATORIES, INC. (US) 1997-02-12 EP disclosed
WO-1996026747-A2 USE OF AMIDOAMINES IN OPHTHALMIC COMPOSITIONS ALCON LABORATORIES, INC. (US) 1996-09-06 WO disclosed
EP-0669803-A1 USE OF AMIDOAMINES IN OPHTHALMIC COMPOSITIONS ALCON LABORATORIES, INC. (US) 1995-09-06 EP disclosed
WO-1995008266-A1 USE OF AMIDOAMINES IN OPHTHALMIC COMPOSITIONS ALCON LABORATORIES, INC. (US) 1995-03-30 WO disclosed
EP-0437006-B1 Composition that protects dyed hair from fading COLGATE PALMOLIVE CO (US) 1994-12-07 EP disclosed
US-5045307-A Sunscreen agents, hydroxybenzophenones, incorporated into shampoo, hair conditioners COLGATE-PALMOLIVE COMPANY (US) 1991-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190099342-A1 COOLING PRODUCT TRPA1, TRPV2, NISCH DNM1 4365/4885FAAH 53/4885LPAR1 3741/4885
US-12629327-B2 Keratin-based hair straightening formulations, methods and systems KRT18, HCN4, COL14A1 DNM1 3619/4885FAAH 3621/4885LPAR1 2979/4885
US-20080025937-A1 Method and composition for permanently shaping hair DNMT3A, DNMT1, NACA DNM1 1517/4885FAAH 1798/4885LPAR1 1881/4885
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL RBP4, LRAT, RARB DNM1 3641/4885FAAH 660/4885LPAR1 709/4885
US-20260096978-A1 A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS PTGS2, PTGES2, PTGS1 DNM1 4837/4885FAAH 464/4885LPAR1 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.